To test the effect of combined EZH2/FGFR inhibition in vivo, mouse mesothelioma cells that were either Bap1-proficient (NC) or -deficient (BNC) were grafted subcutaneously into the flanks of mice and treated with the drug combination. Here, EZH2 is linked to mesothelioma.